Cardiovascular Outcomes Liraglutide (LEADER trial): 13% reduction in major adverse cardiovascular events (MACE) in patients with Type 2 diabetes and high cardiovascular risk Statistically significant cardiovascular protection Semaglutide (SELECT trial): 20% reduction in MACE in patients with obesity and established cardiovascular disease Studied specifically for cardiovascular outcomes in obesity (not just diabetes) Both medications provide cardiovascular protection, but semaglutides evidence is more recent, more robust, and specifically applicable to patients with obesity regardless of diabetes status
2019;5:eaau7201
The healthy lifestyle habits the researchers considered were healthy diet, regular exercise, not smoking, restful sleep, minimal alcohol intake, good stress management, social connection and support, and no opioid use disorder
It can only be legally prescribed for a very limited number of medical conditions, such as HGH deficiency, Prader-Willi syndrome, or wasting syndrome
When the numbers align this closely, it pays to be cautious
Microbial extracellular polymeric substances: ecological function and impact on soil aggregation
